This study presents an integrative informatics framework that effectively maps the polypharmacology of BCR-ABL inhibitors, highlighting their potential for repurposing in neurodegenerative, fibrotic, autoimmune, and metabolic diseases. Here, ABL1 is linked to metabolic disease.